News for Incyte Corporation (I1NC34.SA)

India’s largest drugmaker, which has posted steady mid-to-high single digit growth for the last eight consecutive quarters, is expected to see its revenues increasing 7-8% year-on-year in Q1FY26, according to brokerages Nuvama and Kotak Securities.

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Sanmina Corporation SANM rose sharply during Tuesday's session...

Shares of Sun Pharma will be in focus after the company said its subsidiaries, SPII and Taro, have agreed to pay $200 million to settle an antitrust case in the US. The settlement, part of the ongoing generic drug pricing litigation, grants a full release from all claims filed by End Purchaser Plaintiffs against the firms and their affiliates.

Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a ‘Neutral’ rating on the stock and increased its price target to $62 from $61. The price hike comes as UBS expects higher sales for Incyte’s Niktimvo, a treatment for chronic Graft-versus-Host Disease […]

Sun Pharma shares: In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte Corporation regarding the legal dispute over LEQSELVITM.

GAIL signs long-term LNG agreement, Sun Pharma settles litigation, LIC appoints new CEO, Tata Group's green steel project begins.

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval, Incyte Corporation filed a patent infringement lawsuit against Sun Pharma, alleging that Leqselvi infringed upon its existing patents.

Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater Associates holds over $38 million worth of shares of INCY, which represents 0.18% of its portfolio. Citing uncertainties about the company’s revenue outlook, particularly the long-term sustainability of Jakafi, William Blair analyst Matt Phipps maintained a […]

Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Find out why INCY stock is a Buy.

Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company's new Preside

Ray Dalio began his investing journey at just 12 years old and went on to gain experience at institutions such as the New York Stock Exchange, Dominick & Dominick LLC, and Shearson Hayden Stone.

Incyte Corporation (NASDAQ:INCY) is one of the top 10 S&P 500 winners of the day that Jim Cramer highlighted. Cramer appreciated the new CEO of the company, as he commented: “We then have Incyte. That’s a biotech company. It just got a new CEO, Bill Meury. He’s an industry veteran, known as a deal maker. […]

Incyte Corporation (INCY) has announced a significant leadership transition with the retirement of Hervé Hoppenot as President and Chief Executive Officer, e

Incyte has underperformed relative to its biotech peers over the past year, though Wall Street analysts maintain a cautiously optimistic view on the stock’s outlook.

The FDA has extended its decision timeline for Incyte's ruxolitinib cream, impacting stock prices. Analysts forecast an average price target of $76.07 f

Summary: Incyte (INCY) shares surged 4.5% following promising trial outcomes for its antibody INCA033989. Analysts foresee a potential upside of 7.20% wi

Shares of Incyte Corporation INCY rose sharply in today's pre-market trading. QIAGEN and Incyte disclosed a precision medicine collaboration to develop compani...

Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]

Incyte (INCY) presented promising late-breaking data for INCA033989, a first-in-class therapy for essential thrombocythemia (ET), at the European Hematolog